TITLE:
Proof of Concept in a Case Study of Glioblastoma Multiforme Successfully Treated with IV Quercetin in Combination with Leading Edge Gamma Knife and Standard Treatments
AUTHORS:
M. A. Nezami, Christopher Duma
KEYWORDS:
Quercetin, Glioblastoma, Leading Edge Gamma Knife
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.9 No.6,
June
29,
2018
ABSTRACT: The Stupp protocol has become standard of care for
the treatment of glioblastoma (GBM) (since its publication in 2005) and has led
to some limited survival improvements. This protocol, consists of radiotherapy
and concomitant chemotherapy with temozolomide, an alkylating agent.
Temozolomide + radiation, compared to radiation alone had added in average 3
months additional life span, 16 percent improved survival at 2 years. That said
since 2005, the standard of care has not changed in regards to the treatment of
early diagnosed aggressive or multifocal GBM, and unfortunately the expected survival
is still poor with 75 percent of patients dying in less than 2 years and average
survival of 15 months. In patients with multifocal tumors (such as the case
below) the average survival is even worse with less than 4 months at her age [1]. Here we present a case study of a patient with advanced multifocal, and
rapidly progressing Glioblastoma Multiforme treated with STUPP protocol in
combination with IV Quercetin. The patient experienced improved quality of life
and response, compared to historical data. It is our recommendation to
investigate such combinational approach in patients with Glioblastoma, as in
our case it proved to be safe and effective with improved quality of life and
performance as well as clinical response and survival.